Stocktoria
GENELUX Corp GNLX
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2023-01-26
GENELUX Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating margin | -415175.0% | -396200.0% | -14214.7% | -27.2% |
| Net margin | -401812.5% | -373362.5% | -16645.3% | -47.0% |
| FCF margin | -329575.0% | -270112.5% | -12529.4% | -32.7% |
| Return on assets | -168.9% | -86.0% | -101.4% | -94.1% |
| Return on equity | -278.5% | -113.7% | -145.3% | 14.6% |
| Current ratio | 2.43 | 4.57 | 3.69 | 0.06 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.